LifeStance Health Group (LFST) Reports Q3 Loss, Tops Revenue Estimates

Core Viewpoint - LifeStance Health Group (LFST) reported a quarterly loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a loss of $0.07, and showing improvement from a loss of $0.17 per share a year ago [1] Financial Performance - The company achieved revenues of $312.72 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 3.72% and up from $262.9 million in the same quarter last year [2] - Over the last four quarters, LifeStance Health has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - LifeStance Health shares have declined approximately 8.9% since the beginning of the year, contrasting with the S&P 500's gain of 24.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $308.84 million, and -$0.25 on revenues of $1.22 billion for the current fiscal year [7] - The estimate revisions trend for LifeStance Health is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]